Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04515238
Title Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)
Acronym CLL2-BZAG
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors German CLL Study Group
Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST